AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
白云追月素
发表于 2024-6-26 15:13:22
245
0
0
AstraZeneca announced on June 26 that the National Medical Products Administration of China officially approved Teresa& on June 18, 2024; reg; The combination of pemetrexed and platinum based chemotherapy drugs is used as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) replacement mutation.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Innovation Drug Enterprises on the Science and Technology Innovation Board Welcoming a Harvest Year: Baekje Shenzhou PD-1 New Indications Accepted by FDA
- JAK1 inhibitor Xibico? New indications for age expansion approved in China
- Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
- Dialogue with Qian Jing, Vice President of Jingke Energy: Market oriented ability is crucial for the third and fourth quarters of the industry to show signs of recovery
- AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
- Incidence rate of lung cancer death in women is higher than that in men
- The bladder cancer targeting drug erdafitinib of Johnson&Johnson was approved in the EU
- Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
